Home  >  Press Releases  >  Most Recent
Share

Press Releases

Press release year list 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
December 29, 2010
MADISON, N.J.-Pfizer Animal Health today announced an agreement to acquire Synbiotics Corporation (Pinksheets SYNB.PK), a privately held, Kansas City-based leader in the development, manufacture and marketing of immunodiagnostic tests for companion and food production animals. Veterinary immunodiagnostics, a methodology using antigen-antibody reaction to detect viruses or bacteria in animals, is a sector growing an estimated 8% annually, twice the rate of the animal health industry as a whole. The global immunodiagnostics market is valued at $735 million, according to industry sources. Factors accelerating growth include increasing interest among companion animal owners in monitoring the health and maintaining wellness of their dogs, cats and horses. Likewise, livestock producers, striving to meet increasing worldwide demand for animal-derived food protein, are placing greater emphasis on immunodiagnostics to safeguard the health of livestock animals. “Our acquisition of Synbiotics, ...
November 10, 2010
DURHAM, N.C.-A new animal health research collaboration aimed at finding better ways of preventing and managing disease and advancing sustainable animal agriculture and welfare was announced today by Pfizer Animal Health and the Easter Bush Research Consortium (EBRC) – one of the largest veterinary research and education consortiums in Europe. The collaboration sets a new standard in animal health research and innovation and is backed by funding of approximately $2 million USD over five years. It is a key component of Pfizer’s ongoing global commitment to veterinarians, which involves supporting the profession through continued training and education initiatives, as well as investing in research programmes. "This new collaboration will bring together many of the research leaders in the animal health world, backed by an unrivalled resource. The potential for increasing our knowledge and improving our ability to manage animal health and welfare issues is very exciting," said Dr. Albert ...
July 7, 2010
NEW YORK-As the global dairy industry continues to raise the bar on milk quality, Pfizer Animal Health recognizes a need for easy access to resources to help producers improve their milk quality decision-making. As a result, the company has launched a new online resource — www.milkqualityfocus.com — offering technical and actionable information on mastitis management and milk quality. "We understand the challenges dairy producers face and the constant commitment they must have to manage mastitis and produce high-quality milk," says Dr. Bradley Mills, DVM, Veterinary Operations, Pfizer Animal Health. "With more stringent European Union somatic cell count (SCC) standards on the way, Milk Quality Focus will provide a timely and valuable source of technical, practical and easy-to-use information on mastitis and milk quality." Each month, Milk Quality Focus will feature video perspectives from industry experts, veterinarians, dairy producers and processors on a new topic that incorporates ...
June 11, 2010
Salmonella Newport Cattle Vaccine Also Part of Pfizer Animal Health’s Licensing Agreement NEW YORK-Pfizer Animal Health today furthered its commitment to safe food from cattle by announcing a global licensing agreement with Epitopix that will expand access to its conditionally licensed Escherichia Coli Bacterial Extract vaccine* to U.S. cattle producers this fall. “Pfizer Animal Health supports cattle producers’ continuing strides against harmful bacteria, often the most frequent causes of food borne illnesses in people,” said Juan Ramón Alaix, president, Pfizer Animal Health. “We want more cattle producers to benefit from this important vaccine to help reduce the prevalence and shedding of E. coli.” The U.S. Department of Agriculture (USDA) granted a conditional license last year to Epitopix for this first and only Escherichia Coli Bacterial Extract vaccine available in the U.S. It is labeled for use in cattle to help reduce the prevalence of E. coli O157 in cattle and feces. This ...
May 25, 2010
Acquires Canada-based Microtek, a leading researcher, developer and manufacturer of vaccines for global aquaculture NEW YORK-Pfizer Animal Health today announced its acquisition of Microtek International, Inc., a recognized innovator in aquaculture vaccines, R&D and healthcare diagnostic services. The acquisition further expands Pfizer’s commitment to a safe food supply from healthy beef and dairy cattle, swine, poultry and, now, fish. Total global fish production – largely for human consumption – now exceeds that of pork, poultry, beef or dairy. Farmed fish production is becoming increasingly important in meeting global demand and is anticipated to account for 55% of total fish production by 2017, according to industry sources. “The time is right for Pfizer Animal Health to enter the global market for aquaculture healthcare therapeutics,” said Juan Ramón Alaix, president, Pfizer Animal Health. “The integration of Microtek R&D into Pfizer Animal Health also will allow us to build a ...
March 23, 2010
NEW YORK-Because pet owners may be even more confused this spring about how to safely use topical flea-and-tick control treatments, Pfizer Animal Health is encouraging pet owners to consult with their veterinarian, instead of attempting to manage flea-and-tick control on their own. This month, the U.S. Environmental Protection Agency (EPA) announced new actions to increase the safety of dozens of spot-on pesticide products that the EPA regulates for pet flea-and-tick control. Pfizer Animal Health strongly supports the EPA recommendations. But not all topical flea-and-tick control products for pets are pesticides. The U.S. Food and Drug Administration (FDA) also regulates and advocates safe use of topical medicines for pet flea-and-tick control. “It can be confusing, which is why consulting a veterinarian is so important,” said George Fennell, Vice President, Companion Animal Division, Pfizer Animal Health. “Cats are especially at risk from any owner confusion this spring about ...
February 18, 2010
Customers now have the opportunity to contribute in 2010 NEW YORK-In 2009, Pfizer Animal Health contributed more than $1.3 million to support FFA programs and help fund the American Association of Bovine Practitioners (AABP) Foundation/Pfizer Veterinary Student Scholarships through a unique partnership with veterinarians, animal health suppliers and dealers. Today, Pfizer announces the same program is available for 2010 through March 31. During this time, eligible accounts completing an enrollment form will receive a 1 percent rebate on all Pfizer Animal Health Cattle Products, excluding MGA purchases, invoiced and shipped Jan. 1 through March 31, 2010 to be donated to either the local FFA chapter(s) of their choice or to the AABP Foundation/Pfizer Veterinary Student Scholarship Fund. “Last year’s response from both FFA members and local animal health suppliers was exciting,” says Will Fett, Regional Director, National FFA Foundation. “Contributions like these help strengthen local ...
February 15, 2010
LAS VEGAS-Pfizer Animal Health today announced that the U.S. Food and Drug Administration (FDA) has approved EXCEDE® Sterile Suspension as the first safe and effective, long-acting antibiotic formulation licensed for horses. EXCEDE Sterile Suspension is the newest addition to Pfizer Animal Health’s extensive portfolio of equine products backed by scientific research and innovation in the field of equine medicine. EXCEDE Sterile Suspension is indicated for the treatment of lower respiratory tract infections in horses caused by susceptible bacterial strains of Streptococcus equi ssp. zooepidemicus. EXCEDE acts as a sustained release product that offers an extended duration of action with fewer injections compared to other antibiotic treatments on the market. The low risk of side effects and proven efficacy and safety in an extended release formulation make EXCEDE for horses a true innovation. Veterinarians administer two intramuscular injections to affected horses 4 days apart. ...
February 8, 2010
Pfizer to Expand Veterinary Experience Before Launch Later this Year TOKYO-Pfizer Animal Health today announced it will begin to expand Japanese veterinary experience with IMPROVAC, Pfizer’s successful pork production technology embraced by pig farmers in other countries for more than 10 years. The Japanese Ministry of Agriculture Forestry and Fishery (JMAFF) has approved IMPROVAC as safe and effective for use by veterinarians in pigs throughout Japan. "In the months ahead, the experience gained with IMPROVAC by a group of veterinarians and swine producers will enable Pfizer to support veterinarians throughout the country more effectively when IMPROVAC becomes more widely available for prescription in late 2010,” said Yukihiro Takemoto, Livestock Business Unit Director, Pfizer Animal Health, Japan. Pfizer plans to train and assist veterinarians and their pork producer clients on the proper use of IMPROVAC to help them maximize the value that it can deliver to their operations. About ...
February 1, 2010
SYDNEY-Pfizer Animal Health today announced the completion of the previously-announced divestiture of certain Fort Dodge veterinary assets in Australia to Virbac (Australia) Pty Limited. The financial terms of the transaction were not disclosed. Pfizer divested the assets in compliance with requirements imposed by the ACCC in connection with Pfizer’s acquisition of Wyeth, including the Fort Dodge business, by Pfizer in October 2009. The assets acquired by Virbac consist of the Fort Dodge Australia livestock business, including a range of livestock vaccines and the Cydectin range of sheep and cattle parasiticides, along with a biologicals manufacturing facility at Penrith, NSW. “This transaction is the final divestiture of assets required by the ACCC in relation to Pfizer Inc’s acquisition of Wyeth, including the Fort Dodge Animal Health Business,” said Mr Mike Van Blommestein, General Manager of Pfizer Animal Health in Australia. “With the integration of Wyeth, including the Fort ...
January 14, 2010
First commercially available product from High-Density 50,000-marker panel signifies landmark event for beef industry, greater economic return for beef producers KALAMAZOO, Mich.-A significant milestone in the history of beef genetics occurred today when Pfizer Animal Genetics announced the completion of HD 50K, the beef industry’s first commercially available predictions based on a High- Density panel of more than 50,000 markers. This breakthrough represents significantly greater selection opportunities for owners of black Angus cattle. “Pfizer Animal Genetics is very proud to bring a High-Density panel to the beef industry,” says Dr. Nigel Evans, vice president of Animal Genetics for Pfizer Animal Health. “This is a major event for the industry and our company, and cattlemen now have access to unprecedented genomic selection information that can supplement EPDs to accelerate genetic progress in their herds.” HD 50K reports 14 genomic trait predictions as Molecular Value Predictions ...